Correction for Kovacs et al., "An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline".

Kovacs, Steven J; Ting, Lillian; Praestgaard, Jens; Sunkara, Gangadhar; Sun, Haiying; Stein, Daniel S; Tanaka, S Ken; Villano, Stephen

Kovacs, Steven J; Ting, Lillian; Praestgaard, Jens; Sunkara, Gangadhar; Sun, Haiying; Stein, Daniel S; Tanaka, S Ken; Villano, Stephen.

Afiliação

Kovacs SJ; Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Ting L; Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Praestgaard J; Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Sunkara G; Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Sun H; Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Stein DS; Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Tanaka SK; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Villano S; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.

Antimicrob Agents Chemother ; 65(1)2020 Dec 16.

Article em En | MEDLINE | ID: mdl-33328319

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google